HOUSTON, JULY 14, 2026 ― Researchers at The University of Texas MD Anderson Cancer Center have created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The study provided new insights that may explain why patients with similar diagnoses often have differences in disease progression, treatment response and outcomes.
The study, published in Blood , was co-led by Robert Orlowski, M.D., Ph.D. , professor of Lymphoma/Myeloma and Experimental Therapeutics ; and Linghua Wang, M.D., Ph.D. , professor of Genomic Medicine , executive director and head of the Center for Cellular Language Intelligence , associate member of the James P. Allison Institute ™, and focus area co-lead with the Institute for Data Science in Oncology .
"Our delineation of five distinct tumor microenvironment ecotypes in the bone marrows of patients with plasma cell disorders provides a new framework to understand the critical role of the host immune system in the biology of these diseases," Orlowski said. "Importantly, this information may provide added prognostic value beyond our current models, which predominantly focus solely on tumor cells. We are hopeful this may help guide treatment selection and provide new avenues to improve host immune system health as part of our strategy to ultimately cure myeloma."
Why study the immune microenvironment in multiple myeloma?
Multiple myeloma is a type of blood cancer that develops from plasma cells, which are a type of immune cell found in the bone marrow. Despite advances in treatment, myeloma is still largely incurable, highlighting a need to understand underlying factors of disease progression.
The researchers used advanced single-cell sequencing technologies to analyze bone marrow samples from 235 patients spanning precursor conditions, newly diagnosed disease and relapsed myeloma. The resulting atlas mapped immune cell populations and interactions across the disease spectrum, revealing five distinct subtypes, known as "ecotypes," that have specific features.
How do the five ecotypes affect patient outcomes?
The researchers discovered that the five ecotypes capture meaningful insights into distinct signaling pathways and genetic programs that were not fully explained by disease stage alone. One was marked by limited immune infiltration, while others showed features of immune surveillance, cytotoxic T-cell activity, inflammation or immune cell stress.
These patterns may help explain why some tumors appear more visible to the immune system, while others grow in immune-suppressive environments that are less responsive to immune-based therapies. For example, some ecotypes were linked to tumor burden, survival and response to immunotherapies such as CAR T cell therapy and T cell engagers.
Notably, certain ecotypes that were enriched in advanced disease could already be detected in precursor conditions, meaning there might be a way to stratify patients at risk for future disease progression.
What does this mean for patients with multiple myeloma?
These findings demonstrate that multiple myeloma is shaped not only by cancer cells, but also by the immune cells surrounding them. Factoring in these differences may help researchers better stratify patients and design treatment strategies. The study also points to immune pathways involving inflammation, metabolic stress and immune suppression that could be studied as targets for future combination therapies.
Future studies will validate these ecotypes in larger patient populations to determine if they can be easily measured using available clinical tools. Additional work also is needed to examine whether specific ecotypes could help guide patient selection or treatment strategies.
"This work provides a comprehensive cellular roadmap of the immune landscape across multiple myeloma progression," Wang said. "We hope this atlas will serve as a valuable resource for uncovering new mechanisms and therapeutic vulnerabilities in myeloma."
